HemoTimes May 28, 2019This Biotech Had Positive Data In Gene Therapy — But It Wasn't EnoughBioMarin Pharmaceutical stock dipped Tuesday after its gene therapy results underwhelmed investors and raised "more questions" regarding hemophilia A treatment. CLICK HERE TO READ THE FULL STORYNews0 commentsPost not marked as liked
BioMarin Pharmaceutical stock dipped Tuesday after its gene therapy results underwhelmed investors and raised "more questions" regarding hemophilia A treatment. CLICK HERE TO READ THE FULL STORY
